AstraZeneca PLC (LON:AZN)
London flag London · Delayed Price · Currency is GBP · Price in GBX
10,824
-230 (-2.08%)
Aug 7, 2025, 8:44 AM BST

Despegar.com Statistics

Total Valuation

AstraZeneca has a market cap or net worth of GBP 171.41 billion. The enterprise value is 190.33 billion.

Market Cap171.41B
Enterprise Value 190.33B

Important Dates

The last earnings date was Tuesday, July 29, 2025.

Earnings Date Jul 29, 2025
Ex-Dividend Date Aug 7, 2025

Share Statistics

AstraZeneca has 1.55 billion shares outstanding. The number of shares has increased by 0.06% in one year.

Current Share Class 1.55B
Shares Outstanding 1.55B
Shares Change (YoY) +0.06%
Shares Change (QoQ) -0.13%
Owned by Insiders (%) 0.04%
Owned by Institutions (%) 84.37%
Float 1.54B

Valuation Ratios

The trailing PE ratio is 28.53 and the forward PE ratio is 15.10. AstraZeneca's PEG ratio is 1.37.

PE Ratio 28.53
Forward PE 15.10
PS Ratio 4.16
PB Ratio 5.24
P/TBV Ratio n/a
P/FCF Ratio 21.01
P/OCF Ratio 17.54
PEG Ratio 1.37
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.41, with an EV/FCF ratio of 23.33.

EV / Earnings 31.44
EV / Sales 4.62
EV / EBITDA 13.41
EV / EBIT 18.20
EV / FCF 23.33

Financial Position

The company has a current ratio of 0.86, with a Debt / Equity ratio of 0.74.

Current Ratio 0.86
Quick Ratio 0.66
Debt / Equity 0.74
Debt / EBITDA 1.69
Debt / FCF 2.95
Interest Coverage 10.77

Financial Efficiency

Return on equity (ROE) is 19.67% and return on invested capital (ROIC) is 11.88%.

Return on Equity (ROE) 19.67%
Return on Assets (ROA) 8.28%
Return on Invested Capital (ROIC) 11.88%
Return on Capital Employed (ROCE) 18.19%
Revenue Per Employee 437,329
Profits Per Employee 64,205
Employee Count94,300
Asset Turnover 0.52
Inventory Turnover 1.65

Taxes

In the past 12 months, AstraZeneca has paid 1.26 billion in taxes.

Income Tax 1.26B
Effective Tax Rate 17.17%

Stock Price Statistics

The stock price has decreased by -11.27% in the last 52 weeks. The beta is 0.15, so AstraZeneca's price volatility has been lower than the market average.

Beta (5Y) 0.15
52-Week Price Change -11.27%
50-Day Moving Average 10,627.64
200-Day Moving Average 10,817.40
Relative Strength Index (RSI) 56.76
Average Volume (20 Days) 2,628,420

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, AstraZeneca had revenue of GBP 41.24 billion and earned 6.05 billion in profits. Earnings per share was 3.87.

Revenue41.24B
Gross Profit 33.93B
Operating Income 10.47B
Pretax Income 7.32B
Net Income 6.05B
EBITDA 13.96B
EBIT 10.47B
Earnings Per Share (EPS) 3.87
Full Income Statement

Balance Sheet

The company has 5.19 billion in cash and 24.04 billion in debt, giving a net cash position of -18.85 billion or -12.16 per share.

Cash & Cash Equivalents 5.19B
Total Debt 24.04B
Net Cash -18.85B
Net Cash Per Share -12.16
Equity (Book Value) 32.71B
Book Value Per Share 21.06
Working Capital -3.36B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 9.77 billion and capital expenditures -1.62 billion, giving a free cash flow of 8.16 billion.

Operating Cash Flow 9.77B
Capital Expenditures -1.62B
Free Cash Flow 8.16B
FCF Per Share 5.26
Full Cash Flow Statement

Margins

Gross margin is 82.26%, with operating and profit margins of 25.40% and 14.68%.

Gross Margin 82.26%
Operating Margin 25.40%
Pretax Margin 17.74%
Profit Margin 14.68%
EBITDA Margin 33.85%
EBIT Margin 25.40%
FCF Margin 19.78%

Dividends & Yields

This stock pays an annual dividend of 2.41, which amounts to a dividend yield of 2.14%.

Dividend Per Share 2.41
Dividend Yield 2.14%
Dividend Growth (YoY) 7.81%
Years of Dividend Growth n/a
Payout Ratio 59.51%
Buyback Yield -0.06%
Shareholder Yield 2.08%
Earnings Yield 3.53%
FCF Yield 4.76%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.98
Piotroski F-Score 6